Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Alaeldein M. Abudabos
Total Records ( 5 ) for Alaeldein M. Abudabos
  Alaeldein M. Abudabos
  This study was performed to evaluate the effect of feeding Tomoko, a commercial enzyme supplement that contains an acidic protease, α-amylase, pectinase, phytase, glucoamylase, cellulase and Aspergillus Awamori cells in a standard corn-soy ration for broiler chicken from 1 to 42 day of age. A total of 960 Cobb 500 chicks were randomly distributed in a randomized complete block design among 16 floor pens with 4 replicate pens/treatment. Two levels of diet density (normal and low) and two levels of enzyme (without and with) in a factorial arrangement resulted in four dietary treatments: T1 = normal density diet; T2 = T1+0.05% enzyme; T3 = low density (low energy, low protein diet); T4 = T3+0.05% enzyme. Body weight was significantly affected by diet density and enzyme at 42 d (p<0.001). Enzyme supplementation improved eviscerated, breast and total meat percentages (p<0.01, 0.01 and 0.001, respectively) while diet density had a significant effect on all parts yield measured. Ileal protein retention showed a significant density x enzyme interaction (p<0.005). Serum total protein, calcium and phosphorus were improved as a result of enzyme supplementation. Enzyme was able to restore the nutritional value in the low density diet. These findings suggesting that increased muscle mass is partially responsible for the observed increased in body weight on use of enzyme preparation.
  Alaeldein M. Abudabos , Gamaleldein M. Suliman , Elsayeid O. Hussien , Mu`ath Q. Al-Ghadi and Abdullah Al-Oweymer
  The current study was performed to evaluate the effect of reducing mineral-vitamin (M-V) premix by 50% or substituting it completely with a commercial product (HepatoCare) on broiler performance as well as blood hemato-biochemical parameters. One hundred and twenty, 14-day old unsexed, broiler chickens of Ross 308 strain were used in a randomized complete block design with 3 treatments, 8 replicates per treatment. Chickens were fed on a common starter diet for the first two weeks of age. Three typical corn-soybeans based finisher diets were formulated based on M-V premix level and source and were fed to broilers from 14-35 days. Broilers were assigned to 3 treatments: T1 is commercial M-V premix at the rate of 0.5%; T2 is M-V premix as in T1 but at lower rate of 0.25%; or T3 is HepatoCare Premix (0.1%). Feed intake (FI) and Body Weight Gain (BWG) were measured weekly and Feed Conversion Ratio (FCR) was computed. Results revealed that reduction of the commercial M-V premix from 0.5-0.25% or replacing it with HepatoCare from the finisher diets had no effect on cumulative BWG, FI and FCR (p>0.05). On the other hand, treatment did not affect blood hematology or mineral concentrations in serum (p>0.05). The premix at the rate of 0.5% (T3) provided more quantities of some minerals and vitamins as compared to the strains recommendation. It can be concluded that it`s possible to reduce the dietary M-V premix up to 50% during the finisher period from 14-35 days without jeopardizing the performance which will decrease the cost of feed and as a result reduce the cost of production.
  Alaeldein M. Abudabos , Mutassim M. Abdelrahman , Hany M. Yehia , Muath Q. Al-Ghadi and Ibrahim A. Alhidary
  This study was executed to assess the effect of stocking density on carcass processing yield, small intestine morphometric measurements and ileal bacterial count in female Ross 308 from 0-30 day of age. A total of 96 female Ross chicks were randomly distributed in a randomized complete block design among 12 cages with three dietary stocking densities based on final body weight: low (28.0 kg m-2), medium (37.0 kg m-2) and high (40.0 kg m-2) which was equivalent to 0.050, 0.037 and 0.030 m2/bird, respectively. Results revealed that heavier breasts were obtained from birds which had subjected to the low stocking density (p<0.001). Total small intestine lengths and weights from birds which were subjected to the low density were the longest and the heaviest as compared to the other two groups. Birds in the low and high densities had longer villi in the duodenum and jejunum than did the group in the medium density. Ileal Clostridium perfringens (C. perfringens) and gram negative Bacilli counts in the low density birds tended to be the lowest among all groups (p<0.05). Based on presented evidences it can be concluded that increasing the stocking density of chicks from 28 to 40 kg of BW m-2 resulted in poor performance and could jeopardize their welfare.
  Tariq M. Hantash , Ehab A. Abu-Basha , Dergham A. Roussan and Alaeldein M. Abudabos
  A bioequivalence and pharmacokinetics profiles of two doxycycline powder formulations (Providox® and Doxyvet 0-50 S®) were compared in 24 healthy chickens following administration of a single oral dose (20 mg/kg bw). Serial blood samples were drawn at 10 points after administration to determine doxycycline concentrations in chicken plasma by HPLC/UV. the pharmacokinetics parameters; area under plasma concentration-time curve (AUC0-24), maximum plasma concentration (Cmax) were determined for both formulations. The average means of AUC0-24 and Cmax for Providox® and Doxyvet 0-50 S® were very close (62.32 ± 3.34 and 57.55 ± 4.66 µg.h/ml and 5.36 ± 0.26 and 5.08 ± 0.25 µg/ml, respectively) with no significant differences based on ANOVA. The 90% confidence intervals of the parameters AUC0-24 and Cmax between two formulations were within the range 80 to 125 % of bioequivalence according to US FDA regulation. The relative bioavailability of Providox® compared to Doxyvet 0-50 S® was 108.24%. Therefore, the Providox® and Doxyvet 0 - 50 S® were considered to be bioequivalent.
  Ehab A. Abu - Basha , Saad M. Gharaibeh , Alaeldein M. Abudabos , Ahmad F. Shunnaq and Ahmad M. Al - Majali
  A pharmacokinetic and bioequivalence evaluation of two norfloxacin oral solutions was carried out in healthy broiler chickens after oral administration according to a single dose, randomized, parallel-experimental design. The two formulations were: Vapcotril-10%® (Vapco, Jordan) as a test product and Mycomas 10%® (Univet, Ireland) as a reference product. The chickens were allotted into 3 equal groups (8 chickens/group). Chickens of group 1 and 2 were given a single oral dose of Vapcotril-10%® and Mycomas 10%® at a dose level of 16 mg/kg body weight (bw), respectively after an overnight fasting. Chickens of group 3 were given a single intravenous dose of norfloxacin to calculate the systemic bioavailability. Serial blood samples were collected from the left brachial or cutaneous ulnar veins at different time points post drug administration. Norfloxacin concentrations in chicken plasma were determined using a microbiological assay and Klebsiella pneumoniae ATCC 10031 as a test organism. The pharmacokinetics analysis of the data was performed using non-compartmental analysis based on statistical moment theory (SMT) with the help of computerized WinNonlin program (Version 5.2, Pharsight, CA, USA). The maximum plasma concentration (Cmax), time to reach peak concentration (tmax), area under plasma concentration-time curve (AUC0-12h and AUC0-inf), elimination half-life (t1/2beta) and systemic bioavailability (F) were. 4.94 ± 0.06 and 3.88 ± 0.07 μg/ml, 1.0 and 2.0 h, 21.60 ± 0.54 and 20.51 ± 0.39 μg.h/ml, 25.40 ± 0.76 and 23.40 ± 0.69 μg.h/ml, 4.49±0.13 and 3.87±0.21h, 50 and 47.5% for Vapcotril-10%® and Mycomas 10%®, respectively. The 90% confidence interval for test: reference ratio of the AUC0-12h (99.53-111.15), AUC0-inf (100.9-116.72) and Cmax (122.69-132.15) was within the EMEA bioequivalence acceptance range of 80%–125% for the AUC and 75-133 for the Cmax. In conclusion, Vapcotril-10%® is bioequivalent to Mycomas 10%® and can be used as interchangeable therapeutic agents in veterinary medicine practice.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility